How long should you stay on a GLP-1?

What this guide covers

There is no single tidy number for how long to stay on Ozempic or another GLP-1. Here is what the labels and the evidence actually say, and how to think about it with your prescriber. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The short answer: it is framed as long-term. There is no fixed end date written into the labels for semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). Both obesity and type 2 diabetes are treated as chronic conditions, so these medications are generally framed as long-term treatments rather than a short course, used for as long as they are helping and well tolerated and reviewed regularly. That framing surprises a lot of people who expected a finish line. It helps to think of it the way clinicians do: a treatment you continue while it is doing its job, the same as other long-term medications, not a temporary fix.
• Why there is no single number. The honest reason there is no tidy answer is that the right duration depends on what you are treating, how you respond, how well you tolerate it, your other health conditions, and practical factors like cost and supply. For type 2 diabetes, the medication is managing blood sugar, and stopping hands that job back to your other treatments. For weight management, it is managing appetite, and the appetite biology does not change underneath. Any content promising a clean number of months should be read carefully, because the people who study this do not give one.
• What the evidence says about stopping. The reason the long-term framing exists is what the trials show about stopping. When the drug clears, appetite returns, and a share of what it helped with tends to come back, because the underlying biology has not changed. The STEP-1 extension study is the most-cited source on this pattern, and the STEP-4 trial showed that continuing the medication held results that were largely lost when it was switched to placebo. This is not a comment on willpower; it is evidence that the effect depends on continued treatment, which is exactly why duration is a long-term question.
• Reframing the 'forever' worry. The idea of being on a medication indefinitely unsettles many people, and that is worth sitting with rather than dismissing. The reframe clinicians offer is that long-term does not mean unchangeable: doses can move, including down to a maintenance dose for some people, the plan is reviewed regularly, and it is always a decision you revisit with your prescriber rather than a life sentence. Our long-term GLP-1 guide covers maintenance and coming off in more depth. The goal is to treat duration as an ongoing conversation, not a one-time verdict you are stuck with.
• Making the decision with your prescriber. How long you stay on a GLP-1 is genuinely a shared decision, and a few questions help structure it: Is it still helping and well tolerated? What would the plan be if you needed to stop for cost, supply, surgery, or pregnancy? Are you at a point where a maintenance dose makes sense? The FDA labels and the trial extensions are the evidence base, but they cannot weigh your specific situation, only your clinician can do that with you. If you are stopping for a side effect, say so rather than simply quitting, because a dose change may solve it.

Frequently asked questions